Director Hta Statistics & Rwe Methods

Johnson & Johnson Johnson & Johnson · Pharma · Beerse, Antwerp, Belgium +3

The Director HTA Statistics & RWE Methods role at Johnson & Johnson provides strategic and technical leadership for data generation initiatives in innovative medicines. Responsibilities include dataset feasibility, protocol development, study design, and dissemination of results for indirect treatment comparisons, post hoc trial analyses, and real-world evidence (RWE). The role supports market access and launch strategies by leading the design of advanced study designs and statistical analyses aligned with Payer/HTA expectations. It also involves contributing to capability building, including training on Payer/HTA requirements and new methodologies, and development of coding libraries and AI/ML advanced analytics scaling and platforms.

What you'd actually do

  1. Maintain deep expertise in evolving methodologies, including proactive awareness of regulatory, Payer/HTA, and guideline/formulary evidentiary requirements.
  2. Review, synthesize, and disseminate external case studies and precedents to shape internal strategy and analyses.
  3. Act as key reviewer for the Global RWE Methods Review Board, ensuring robust governance and methodological consistency across programs.
  4. Lead the design of advanced study designs and statistical analyses aligned with Payer/HTA expectations (e.g., indirect treatment comparisons, causal inference methods, surrogate endpoint validations, etc.) to support market access and launch strategies for key assets.
  5. Provide key contributions to capability building, including training for team on Payer/HTA requirements and new methodologies and also in the development of coding libraries and AI/ML advanced analytics scaling and platforms, etc.

Skills

Required

  • Postgraduate degree (MSc, PhD) in Biostatistics, Epidemiology, Data Science, Health Economics, or related field
  • Minimum 8 years of relevant experience in pharmaceutical, biotech, or consulting environments
  • Demonstrated experience in advanced statistical methodologies relevant for Payer/HTA evidence generation including indirect treatment comparisons and RWE.
  • Deep expertise in clinical trial design and the strengths and limitations of secondary data sources (claims, EMR, registries, surveys)
  • Advanced knowledge of statistical methodologies for market access, including indirect treatment comparisons and causal inference approaches
  • Strong understanding of methodological standards, regulatory and Payer/HTA frameworks and their application to evidence generation.
  • Hands-on proficiency in statistical programming (SAS, R; desirable)
  • Able to organize work into clear project plans with defined milestones, deliverables, and resources

Nice to have

  • PhD, PharmD, or MD
  • Agility Jumps
  • Commercial Awareness
  • Competitive Landscape Analysis
  • Developing Others
  • Global Market
  • Health Economics
  • Health Intelligence
  • Inclusive Leadership
  • Leadership
  • Market Knowledge
  • Market Opportunity Assessment
  • Operations Management
  • Performance Measurement
  • Pricing Strategies
  • Program Management
  • Regulatory Compliance
  • Strategic Change

What the JD emphasized

  • methodologies
  • Payer/HTA
  • evidence generation
  • statistical analyses
  • AI/ML advanced analytics scaling and platforms